Program includes research collaboration with Metro State University

DALLAS, Aug. 20, 2024 — GetChkd Inc. announces it has been selected by AFWERX for a STTR Phase II in the amount of $1.7MM focused on Blockchain Infrastructure to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and on August 16, 2024, GetChkd Inc. started its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.

“The opportunity to extend the use of our Blockchain Infrastructure Platform, while also accelerating commercialization in the private sector, is a significant milestone for GetChkd,” said Michael Caplovitz, Founder and CEO of GetChkd. “We are honored to collaborate with AFWERX and researchers at Metro State University to advance this technology.”

“The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.”

About GetChkd Inc.
GetChkd’s state-of-the-art blockchain infrastructure platform revolutionizes system connectivity, enforces user-specific mappings, and ensures immutable audit trails for every action. This guarantees unparalleled security, accountability, and reliability for a connected system of systems across various domains and classifications. GetChkd: The Foundation of Trust in a Connected World.

About Metro State University
Metro State University in conjunction with MN Cyber (Minnesota) is specialized in IoT security, foreign adversary censorship, and network security. Metro State is recognized as an NSA Designated Center for Excellence in Cyber Defense (NCAE-CD).

About AFRL
The Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space and cyberspace force. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com.

About AFWERX
As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at five hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has executed over 6,100 new contracts worth more than $4 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: www.afwerx.com. 

Company Press Contact:
Michael Caplovitz
Founder and CEO, GetChkd Inc.
[email protected]
833-405-3335

SOURCE GetChkd Inc.

Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet

RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 — Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round.

The oversubscribed financing was led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.  

“Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” said Neal Fowler, Chief Executive Officer at Pathalys Pharma, Inc. “We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys.  We are immensely grateful for the continued support of our investors and remain steadfast and confident in our mission to bring upacicalcet forward to patients.”

“I am thrilled to support the Pathalys Pharma team in bringing upacicalcet to dialysis patients with ESKD who need improved calcimimetic treatment options,” stated Chen Yu, M.D., Founder and Managing Partner of TCGX. “With both upacicalcet trials on track for early completion, we are hopeful that these efforts will support a near-term NDA filing with the FDA. I am excited to be a part of this journey as a member of the Pathalys board.”

The funds raised via this financing will be utilized to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations.  Joining the Board of Directors as members will be Dr. Chen Yu and Mr. Joe Siletto, Managing Partner of JP Morgan Life Sciences Private Capital.  Additionally, Dr. Roger Zhang, Ph.D. of Samsara BioCapital will join the Board as an observer. 

“We are excited to have Chen and Joe join our Board and support Pathalys’ efforts to develop innovative medicines aimed to improve the lives of patients with kidney disease. We are confident that their extensive financial markets experience and leadership will further complement our current Board,” commented BT Slingsby, M.D., Ph.D., M.P.H., Co-founder, and Executive Chairperson of Pathalys and Founder of Catalys Pacific.

ABOUT PATHALYS PHARMA
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of ESKD. Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group and is headquartered in Research Triangle Park, North Carolina.

For more information about Pathalys, please visit pathalys.com.

ABOUT TCGX

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in Palo Alto and New York City.

For more information, please visit www.tcgcrossover.com

SOURCE Pathalys Pharma

to deploy next-generation power plants to the grid edge

WASHINGTON, Aug. 20, 2024 — Today, Distributed Sun (DSUN) announces $37.5 million of new working capital to spin-out and ramp operations of its New Energy Investment Company (NEIC), truCurrent. Standing atop 15 years of best practice leadership, business model innovation and proven, consistent asset yield performance, truCurrent offers Fortune 1000 companies – large fleet and facility operators – the know-how to make and execute better energy choices, mitigate operating and financial risks, and realize best-value, bottom-line rewards from smart energy transitions.

“We build better roadmaps so our partners can navigate smarter roadtrips to their intended energy destinations. The results are carbon and cost savings, energy choice and load flexibility for our customers,” says Chase Weir, CEO of DSUN and truCurrent. “We design enterprise-wide when deploying new energy asset infrastructure. Our solutions create, and extract, superior value by delivering the right combination of on- and off-site distributed energy resources to optimize carbon usage, cost and competitive advantages for our clients.” truCurrent balances the goals and needs of customers’ core functions including fleet and facility operations, finance and treasury, real-estate and construction, corporate leadership, sustainability, governance, and transformation – as well as those of their shareholders.

truCurrent designs roadmaps that simplify decision-making and drive the implementation of on-time and on-budget deployments to active operating sites. At the heart of the roadmaps is a deep understanding of the ways in which new energy asset technologies pose different integration and operational risks, and have different use-cases, useful lives, performance profiles, operating requirements and more. To facilitate cost-effective and tax-efficient capital expenditures truCurrent manages the complex patchwork of state, local and federal frameworks across the U.S.

Utilities stand to make significant gains alongside their largest customers as truCurrent smart microgrid and virtual power controls are deployed with new generation storage and load assets to the distribution grid edge. “We engage with utilities early in the process to provide visibility into the needs of their largest customers. We show how our investments help accelerate shared goals – reducing carbon intensity for the customer and the grid, increasing revenues while optimizing energy costs, providing grid services, and investing in the resiliency of their grids, all while allocating capital more efficiently,” says Jeff Weiss, Executive Chairman of DSUN and truCurrent.

In Q4, truCurrent will announce new strategic capital and F1000 partnerships, and its new executive leadership team members. In recent weeks, the company has onboarded chief commercial and transformation officers, a chief of staff, and finance, policy, development, delivery, engineering and product development veterans, with a chief financial officer and more joining later in 2024. Incubated since 2022, and officially launched in 2024, the business operates as a separate entity – with independent treasury, capital accounts, intellectual property, service offerings, governance and staff.

About truCurrent
For more information about the company’s initiatives, services, and career opportunities, please visit www.trucurrent.com.
About Distributed Sun
For more information about the company’s initiatives, services, and career opportunities, please visit distributedsun.com.

For more information:
[email protected]

SOURCE Distributed Sun

BOSTON and HOUSTON, Aug. 20, 2024 — Swift Current Energy (“Swift Current”) announced today that it has closed on a tax equity investment from Google for its landmark 800 MWdc (593 MWac) Double Black Diamond Solar project (“the Project”) in southern Illinois.

Once operational, Double Black Diamond Solar is expected to be the largest solar project east of the Mississippi River. The tax equity financing utilizes Energy Communities and domestic content adders, provided in the Inflation Reduction Act. Located 30 miles west of Springfield, Illinois, the Project is currently under construction and is expected to reach commercial operations by early 2025.

Swift Current previously announced that Mitsubishi UFJ Financial Group (MUFG), Societe Generale, Truist and ING provided construction financing for the Project. Swift Current is the project developer and will be the long-term owner and operator.

Eric Lammers, CEO and Co-Founder of Swift Current, said, “Projects of Double Black Diamond Solar’s magnitude require innovative partnerships. We are delighted to join forces with Google on a ground-breaking structure that will support Double Black Diamond Solar and serve as a guide for other major projects to come.”

Amanda Peterson Corio, Global Head of Data Center Energy at Google, said, “As we work to responsibly grow our infrastructure, we need to partner with companies like Swift Current who understand the nuances of the energy markets where we operate and can help unlock new clean energy at a rate that matches the pace and scale of demand growth on electric grids today.”

At peak construction, the Project employed approximately 500 construction workers. Swift Current selected McCarthy Building Companies, Inc. as the engineering, procurement, and construction (EPC) partner. The Project utilizes First Solar modules, a majority of which are being manufactured in the US, as well as solar trackers from U.S.-based Nextracker.

During its operational life, Double Black Diamond Solar will contribute to communities in Sangamon and Morgan counties. The Project, capable of powering 100,000 homes annually, is expected to reduce regional carbon dioxide emissions by approximately one million tons per year.

Sangamon County Board Chairman Andy Van Meter said, “We are proud to be home to one of the largest clean energy projects in the nation. The Double Black Diamond Solar project brings significant economic benefits to our community, contributing $100 million in tax revenue and supporting hundreds of jobs. This project is a win for both our community and the environment.”

Constellation NewEnergy, Inc. will purchase a portion of the energy and RECs generated by Double Black Diamond Solar to serve the seven customers that have been announced. The City of Chicago will source renewable energy produced by the Project to power several energy-intensive facilities, including Chicago O’Hare International Airport and Midway International Airport. Additionally, Cook County Illinois, CVS Health, Loyola University of Chicago, PPG, State Farm, and TransUnion have agreements to purchase power from the Project via Constellation.

Vinson & Elkins LLP and Husch Blackwell LLP represented Swift Current in the transaction. Milbank LLP and Bryan Cave Leighton Paisner LLP represented Google.

About Swift Current Energy

Swift Current Energy is trailblazing a path for clean energy now. Founded in 2016, the company develops, owns and operates highly competitive, utility-scale wind, solar and energy storage projects across the United States. Swift Current Energy is majority-owned by Buckeye Energy Holdings, with the other owners being IFM Net Zero Infrastructure Fund and Lookout Ridge Energy Partners. For more information, please visit swiftcurrentenergy.com.

SOURCE Swift Current Energy

Funding Co-Led by Inovia Capital & Tola Capital Brings AI-Driven Software to the Biopharma Industry With First Product Reliant Tabular

MONTREAL and BERLIN, Aug. 20, 2024 — Reliant AI, a provider of gen AI-powered data analytics software, announced today its launch out of stealth with $11.3 million in seed funding. The new capital was co-led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi.

Reliant AI was created by leading Natural Language Processing and Reinforcement Learning  scientists and researchers Karl Moritz Hermann, Marc Bellemare and Richard Schlegel who led teams at DeepMind, Google Brain and EY Parthenon. They’re passionate about how generative AI can solve information challenges to reduce repetitive mental labor and accelerate decision making for enterprises. The company is initially targeting the biopharma industry and will use the new funding to hire engineering talent to expand its technology investment and footprints in Europe and North America.

“Information and data are a critically overlooked part of making the life sciences progress to bring about a better world. The sheer amount of menial labor involved in data-intensive industries today means that many highly skilled professionals are focused on wrangling data, rather than solving complex issues. We created an AI system that understands the life sciences to radically grow its capacity to perform research at scale,” said Karl Moritz Hermann, CEO and Co-Founder of Reliant AI.

Reliant AI’s first product, Reliant Tabular, is an AI workbench that is attracting significant interest across key business segments in the biopharma industry. The product helps life science analysts find scientific evidence for their decisions through automated systematic reviews, asset scans, comprehensive analyses, and a customizable data platform – with Reliant AI, anything can be queried.

Features of Reliant Tabular include:

• Proprietary ML models optimized to be experts in biopharma topics
• Comprehensive approach to fact-finding – maximizing recall so that nothing gets missed
• User interface that makes it quick and easy to reconcile generated results with ground truth evidence
• Answers in a report-ready format so that teams can collaborate on analyses

“The biopharma industry has a massive and underserved information need. Reliant AI blends cutting-edge research with domain expertise to create software that makes it possible for a day’s worth of data wrangling to be done in 30 seconds. Marc, Karl Moritz and their technical team bring together decades of AI expertise from the world’s best research groups, such as DeepMind, Google Brain, and Meta, giving Reliant the ability to really move the needle on the application of generative AI to hard data problems,” said Aaron Fleishman, Partner at Tola Capital.

“We see a significant market opportunity in the pharmaceutical sector, as companies strive to build and partner with new entrants to develop innovative solutions like those offered by Reliant AI,” said Steve Woods, Partner at Inovia Capital. “This notable demand in a large and growing market underscores the potential of AI to drive impactful advancements in the biopharma industry.”

“Reliant AI has significantly increased my efficiency by rapidly parsing relevant data, allowing me to focus on deeper analysis and faster turnaround times. This technology promises to revolutionize how early commercial assessments are conducted,” said Miguel Silva, Strategy Director at OMass Therapeutics.

To learn more or obtain a demo, visit https://www.reliant.ai/

About Reliant AI

Reliant AI is a provider of genAI-powered data analytics software that accelerates secondary research in biopharma. With Reliant AI, anything can be queried. The company was created by Karl Moritz Hermann, Marc Bellemare and Richard Schlegel, renowned scientists and researchers who previously led teams at DeepMind, Google Brain and EY Parthenon. Reliant AI has offices in Berlin, Germany and Montreal, Canada and has raised USD $13.5M in total funding from investors including Tola Capital, Inovia Capital, Mike Volpi, Amit Agarwal, and AI pioneer Yoshua Bengio.

About Tola Capital

Tola Capital is a venture capital firm that believes in the power of software, data, and AI to transform the way the world works. Founded in 2010 by experienced software operators at the forefront of cloud computing’s rise, the firm backs entrepreneurs who have enterprise technology experience and are building disruptive, industry transforming solutions with diverse teams. Tola Capital has successfully exited numerous startups, and continues to evolve as it supports founders into the era of AI. Visit www.tolacapital.com for more information.

About Inovia Capital

Inovia Capital is a venture capital firm that partners with founders to build impactful and enduring global companies. The team leverages an operator-led mindset to provide founders with multi-stage support, mentorship, and access to a worldwide network. Inovia manages over US$2.2B with operations in Montreal, Toronto, Calgary, Bay Area, and London. For more information, visit inovia.vc.

Media Contact: Nicole Brunet, 408-761-1803, [email protected]

Logo – https://mma.prnewswire.com/media/2482483/Reliant_AI_Inc__GEN_AI_ANALYTICS_PROVIDER__RELIANT_AI__LAUNCHES.jpg

Finanzierung durch Inovia Capital & Tola Capital bringt mit dem ersten Produkt Reliant Tabular KI-gesteuerte Software in die Biopharma-Industrie

MONTREAL und BERLIN, 20. August 2024 — Reliant AI,, ein Anbieter von KI-gestützter Datenanalysesoftware, gab heute den Start aus dem Stealth-Modus mit einer Seed-Finanzierung von 11,3 Millionen US-Dollar bekannt. Das neue Kapital wurde gemeinsam von Tola Capital und Inovia Capital geleitet, mit Beteiligung des Angel-Investors Mike Volpi.

Reliant AI wurde von führenden Wissenschaftlern und Forschern der Bereiche Natural Language Processing und Reinforcement Learning  Karl Moritz Hermann, Marc Bellemare und Richard Schlegel entwickelt, die Teams bei DeepMind, Google Brain und EY Parthenon geleitet haben. Sie sind begeistert davon, wie generative KI Informationsprobleme lösen kann, um repetitive Denkarbeit zu reduzieren und die Entscheidungsfindung für Unternehmen zu beschleunigen. Das Unternehmen zielt zunächst auf die biopharmazeutische Industrie ab und wird die neue Finanzierung nutzen, um technische Fachkräfte einzustellen und seine Technologieinvestitionen und Präsenz in Europa und Nordamerika zu erweitern.

„Informationen und Daten sind ein übersehener Teil des Fortschritts in den Biowissenschaften, um eine bessere Welt zu schaffen. Die schiere Menge an Arbeit, die heute in datenintensiven Branchen anfällt, bedeutet, dass sich viele hochqualifizierte Fachkräfte auf die Verwaltung von Daten konzentrieren, anstatt komplexe Probleme zu lösen. Wir haben ein KI-System entwickelt, das die Biowissenschaften versteht, um seine Kapazität zur Durchführung von Forschung in großem Maßstab radikal zu steigern”, sagt Karl Moritz Hermann, Geschäftsführer und Mitbegründer von Reliant AI.

Das erste Produkt von Reliant AI, Reliant Tabular, ist eine KI-Workbench, die in wichtigen Geschäftsbereichen der Biopharma-Industrie auf großes Interesse stößt. Das Produkt unterstützt Life-Science-Analysten bei der Suche nach wissenschaftlichen Belegen für ihre Entscheidungen durch automatische systematische Überprüfungen, Asset-Scans, umfassende Analysen und eine anpassbare Datenplattform – mit Reliant AI kann alles abgefragt werden.

Die Funktionen von Reliant Tabular umfassen:

• Proprietäre ML-Modelle, die als Experten für Biopharma-Themen optimiert sind
• Umfassender Ansatz zur Tatsachenermittlung – Maximierung des Erinnerungsvermögens, damit nichts übersehen wird
• Benutzeroberfläche, die einen schnellen und einfachen Abgleich der generierten Ergebnisse mit den tatsächlichen Gegebenheiten ermöglicht
• Antworten in einem berichtsfähigen Format, sodass die Teams bei der Analyse zusammenarbeiten können

„Die Biopharmabranche hat einen enormen und nicht gedeckten Informationsbedarf. Reliant AI verbindet Spitzenforschung mit Fachwissen, um eine Software zu entwickeln, die es ermöglicht, die Datenverarbeitung eines ganzen Tages in 30 Sekunden zu erledigen. Marc, Karl Moritz und ihr technisches Team bringen jahrzehntelange KI-Expertise aus den weltbesten Forschungsgruppen wie DeepMind, Google Brain und Meta mit, was Reliant in die Lage versetzt, die Anwendung generativer KI auf schwierige Datenprobleme wirklich voranzutreiben”, sagte Aaron Fleishman, Partner bei Tola Capital.

„Wir sehen eine bedeutende Marktchance im pharmazeutischen Sektor, da sich Unternehmen bemühen, neue Marktteilnehmer aufzubauen und mit ihnen zusammenzuarbeiten, um innovative Lösungen wie die von Reliant AI zu entwickeln”, sagte Steve Woods, Partner bei Inovia Capital. „Diese beachtliche Nachfrage in einem großen und wachsenden Markt unterstreicht das Potenzial von KI, die Biopharma-Industrie entscheidend voranzubringen.”

„Reliant AI hat meine Effizienz durch die schnelle Analyse relevanter Daten erheblich gesteigert, sodass ich mich auf tiefergehende Analysen und schnellere Bearbeitungszeiten konzentrieren kann. Diese Technologie kann die Art und Weise, wie frühe kommerzielle Bewertungen durchgeführt werden, revolutionieren”, sagte Miguel Silva, Strategieleter bei OMass Therapeutics.

Um mehr zu erfahren oder eine Demo zu erhalten, besuchen Sie https://www.reliant.ai/

Informationen zu Reliant AI

Reliant AI ist ein Anbieter von genAI-gestützter Datenanalysesoftware, die die Sekundärforschung in der Biopharmazie beschleunigt. Mit Reliant AI kann alles abgefragt werden. Das Unternehmen wurde von Karl Moritz Hermann, Marc Bellemare und Richard Schlegel gegründet, renommierten Wissenschaftlern und Forschern, die zuvor Teams bei DeepMind, Google Brain und EY Parthenon leiteten. Reliant AI hat Büros in Berlin und Montreal, Kanada, und hat insgesamt 13,5 Mio. USD von Investoren wie Tola Capital, Inovia Capital, Mike Volpi, Amit Agarwal und dem KI-Pionier Yoshua Bengio erhalten.

Informationen zu Tola Capital

Tola Capital ist eine Risikokapitalgesellschaft, die an die Kraft von Software, Daten und KI glaubt, um die Welt zu verändern. Das Unternehmen wurde 2010 von erfahrenen Softwareanbietern gegründet, die an der Spitze des Aufstiegs des Cloud Computing standen, und unterstützt Unternehmer, die über Erfahrungen in der Unternehmenstechnologie verfügen und mit verschiedenen Teams bahnbrechende, branchenverändernde Lösungen entwickeln. Tola Capital hat zahlreiche Startups erfolgreich verlassen und entwickelt sich weiter, um Gründer in der Ära der KI zu unterstützen. Besuchen Sie www.tolacapital.com für weitere Informationen.

Informationen zu Inovia Capital

Inovia Capital ist eine Risikokapitalgesellschaft, die mit Gründern zusammenarbeitet, um wirkungsvolle und dauerhafte globale Unternehmen aufzubauen. Das Team nutzt eine betreiberorientierte Denkweise, um Gründern Unterstützung in mehreren Phasen, Mentoring und Zugang zu einem weltweiten Netzwerk zu bieten. Inovia verwaltet mehr als 2,2 Mrd. US-Dollar mit Niederlassungen in Montreal, Toronto, Calgary, Bay Area und London. Weitere Informationen finden Sie unter inovia.vc.

Medienkontakt: Nicole Brunet, 408-761-1803, [email protected]

Logo – https://mma.prnewswire.com/media/2482483/Reliant_AI_Inc__GEN_AI_ANALYTICS_PROVIDER__RELIANT_AI__LAUNCHES.jpg

KUOPIO, Finland, Aug. 20, 2024 — Bone Index Finland Ltd, a pioneering company in medical technology, proudly announces the completion of its latest financing round and a strategic partnership with Lynx Financial (HK) Limited. This partnership aims to enhance Bone Index’s distribution and service capabilities in North America and Asia Pacific.

The newly secured funds will bolster Bone Index’s infrastructure and operations, meeting the growing demand for its innovative bone health diagnostics solutions in these key markets. The financing round, led by Lynx Financial, participated by other European financial investors and existing shareholders, highlights Bone Index’s commitment to further product offerings and services. Bone Index core technology enables quick and accurate measurements of bone health, in both early screening and hospital settings. The company’s product has achieved early commercialization and adoption in Europe and the US. The partnership with Lynx Financial is a major strategic decision for Bone Index as the company to expand its product line and market outreach.

Statements from Leadership

Janne Karjalainen, CEO of Bone Index, expressed his enthusiasm for the strategic partnership and financing round: “This investment and partnership with Lynx Financial are pivotal steps in our growth journey. The funds will significantly enhance our distribution and service capabilities in North America and Asia Pacific, allowing us to bring our state-of-the-art bone health diagnostics to a larger audience. We are excited about the opportunities this collaboration brings and are committed to delivering impactful health solutions globally.”

Tero Silvola, Chairman of the Board of Bone Index, added: “We are thrilled to have Lynx Financial join us as a partner. Their extensive experience in business development, particularly in the healthcare sector, will be invaluable as we expand our operations. Lynx’s expertise and strategic insights will significantly accelerate our growth and help us achieve our vision.

Donald Xu, Managing Director of Lynx Financial, commented: “We are excited about the potential of Bone Index’s innovative diagnostics technology. Bone Index’s solution is accurate and accessible and can democratize the way osteoporosis is detected and diagnosed for consumers and patients. We believe Bone Index is poised for significant growth and market penetration. We are committed to supporting Bone Index to achieve its visions, in Asia Pacific and globally.

About Bone Index

Bone Index Finland Oy is at the forefront of medical technology innovation, dedicated to developing and commercializing advanced bone health diagnostic solutions. The company’s flagship product, the Bindex^® system, is a revolutionary point-of-care device that provides accurate and rapid osteoporosis diagnostics. Bindex^® measures the cortical bone thickness of the tibia, allowing for quick and reliable estimation of bone mineral density at the hip. This portable, pocket-sized device has a 90% accuracy rate, making it comparable to traditional DXA scans and enabling early diagnosis and treatment of osteoporosis. In addition, the technology has applications in various orthopedics treatment settings.  The device’s ease of use and immediate results significantly enhance patient care and reduce healthcare costs.

About Lynx Financial

Lynx Financial is a boutique investment and investment banking firm that specializes in Life Sciences and Medical Technology sectors. With a global outreach and on-the-ground presence, Lynx Financial fully leverages its expertise in deal structuring and investments to help emerging innovative companies from around the world gain access to funding and strategic resources in Asia Pacific regions.

For more information:

Bone Index:
Janne Karjalainen, CEO
[email protected]
+358 45 896 2650

Lynx Financial:
Rio Hong, Associate
[email protected]

Photo – https://mma.prnewswire.com/media/2484586/Bindex.jpg
Logo – https://mma.prnewswire.com/media/2484585/Bindex_Logo.jpg

SOURCE BONE INDEX FINLAND

Amulet’s newly female-majority board positions the company for stronger performance and more robust health outcomes

MADISON, Wis., Aug. 19, 2024 — Amulet, the company shining a light on invisible threats in our food system, today announced the addition of two distinguished members to its Board of Directors: Darcey Nett, Principal at HealthX Ventures, and Lisa Strovink, Managing Partner at AllerFund. These appointments reflect Amulet’s resolve that everyone – from individuals needing better tools to manage their food allergies and intolerances to businesses seeking ways to improve the safety of their food supply chains – benefits from women leaders’ contributions to healthcare technology development.

The company’s board appointments and recent funding round are significant:

• Amulet is one of 14 active, Wisconsin-based, female-founded companies that have raised more than $1M in venture capital.
• Historically, only 20 female-founded companies in Wisconsin have raised more than $1M in venture capital.
• Three out of five of Amulet’s board members are now women, making it a rare female-majority board, particularly in Wisconsin, where women represent just one-quarter of board seats.

“Women’s perspectives are an undervalued asset across tech, business, and health leadership,” said Abi Barnes, Founder and CEO of Amulet. “Female-majority boards aren’t the norm, and we are proud to be participating in a shift of that paradigm – especially with proven investors and visionaries as sharp, dedicated, and accomplished as Darcey and Lisa.”

Experienced health tech leaders 
Darcey Nett is a Principal at HealthX Ventures and is a seasoned start-up executive and entrepreneur. She began her career in enterprise sales at Pfizer before successfully founding, operating, and selling an in-home care business. Transitioning to venture-backed companies, Darcey served as CEO of both ImageMover and Huddle Up (formerly DotCom Therapy), where she boosted revenue and secured $18M in funding, including Bain Capital’s first Wisconsin investment. She also forged partnerships with industry leaders like McKesson, IBM, Philips, and Intuitive. With deep operating experience in revenue-generating roles at a wide range of early-stage health tech companies, Darcey combines a wealth of industry knowledge with hands-on expertise.

“Driving impact has always been my North Star, and throughout my career, I’ve seen how empowering individuals with technology that uncovers hidden insights can improve health outcomes,” said Darcey Nett. “I look forward to working with such a talented team and am confident that with our combined expertise, business acumen, and lived experiences, we can maximize the impact of Amulet’s promising technology.”

Lisa Strovink, Managing Partner at AllerFund, the first venture capital firm investing solely in innovation in food allergy, has spent her career working to bring new therapies to market, focusing on early-stage healthcare technology. Before AllerFund, she was the Chief Strategy Officer at the New York Stem Cell Foundation Research Institute (NYSCF), where she oversaw partnerships, grew strategic operations, and launched and ran cell therapy programs.  

Prior to NYSCF, Lisa evaluated therapeutic investment opportunities at Ascent Biomedical Partners as Principal, led strategic and operational teams at Johnson & Johnson as the Director of Strategic Planning for the Medical Devices and Diagnostics group, was the Director of U.S. Marketing for Cordis Endovascular, as well as the Director of the Carotid Stent Program, and advised early-stage medical technology companies at McKinsey & Company.

“Amulet was one of AllerFund’s first investments. We saw the massive potential the technology holds for community impact,” said Lisa Strovink. “Abi and her team are well-positioned to improve the quality of life for so many people with food allergies and intolerances around the world.”

For more information about Amulet and its growing team, please visit https://www.amulet-inc.com/.

About Amulet 
Amulet equips individuals and businesses with portable sensor technology that uses rapid, on-site molecular detection to quickly identify allergens and environmental contaminants in food.

Amulet is the company behind Allergy Amulet™, a brand with a signature wearable that enables people to test for food allergens on the go, and Amulet Scientific™, a commercial brand with a detection platform that empowers restaurants, suppliers, manufacturers, and other food industry businesses to identity a range of molecular targets like food toxins and environmental contaminants.

About Allergy Amulet
Allergy Amulet™ helps take the worry off your plate with the Amulet, a wearable miniaturized consumer food sensor that tests for common allergenic ingredients in seconds. Whether on a keychain, a necklace, a wristband, a backpack, or in a pocket, the Amulet’s sleek and portable design allows users to savor life’s important moments safely and simply. Learn more at www.allergyamulet.com.

About Amulet Scientific
Amulet Scientific™ is committed to improving the safety and transparency of the food supply chain by offering streamlined detection capabilities for the food, beverage, and agriculture industries. Their debut product is a thumb-sized, battery-powered potentiostat. It features a small display, internal memory, and Bluetooth connectivity. The Amulet unlocks new in-field electrochemical opportunities for developing affordable diagnostics, sensors, and wearable devices. Learn more at www.amuletscientific.com.

MEDIA CONTACT: 
Tess Pawlisch
608-333-9788
[email protected] 

SOURCE Amulet

SEATTLE, Aug. 19, 2024 — Mudstack, the leading provider of file versioning and asset management tools for the game industry, today announced the successful closing of a $4 million financing round. This latest round of funding will be instrumental in accelerating Mudstack’s mission to streamline production workflows and enhance collaboration within game development teams.

In conjunction with the financing, Mudstack is also excited to welcome James Gwertzman as its new Chief Executive Officer. James, the former co-founder and CEO of PlayFab, brings a wealth of experience in the gaming industry and a strong track record of building innovative tools and infrastructure for games.

“I am incredibly excited to join Mudstack at such a pivotal time in its growth,” said James. “It’s crazy to me that our industry is so mature, yet basic tools for managing content and production pipelines are still lacking. I’ve wanted to build an ‘operating system for game studios’ for a long time, and am thrilled to be working with this talented team to deliver on that vision.”

“We couldn’t be happier to have James join us,” said Jordan Stevens, co-founder of Mudstack, and former CEO. “He is truly the dream partner to lead Mudstack into the future vision we both share, freeing me to focus entirely on delighting customers as the new Head of Product.”

The financing round was led by Anthos Capital, with participation from Khosla Ventures, A16Z GAMES, Pioneer Square Labs, and Hyperplane.

“We are thrilled to invest in Mudstack because we see a massive opportunity here,” said Zack Zaharis, Partner at Anthos Capital. “The game development process is becoming increasingly complex, and Mudstack is perfectly positioned to become the go-to solution for teams needing robust, intuitive tools to streamline that process. With James Gwertzman at the helm, we are confident that Mudstack is poised to become an indispensable tool for game developers worldwide.”

In addition, Mudstack has recently signed its first two large enterprise customers, Metacore and Paradox Studios, marking a significant milestone in its growth.

“Mudstack has saved us a significant amount of time spent managing our game assets,” said Petter Lundh, Managing Art Director at Paradox Studios. “It’s also simple enough for artists to use without training, which will make it easy for us to roll it out across more of our internal studios.”

Mudstack will use the newly secured funds to further develop its platform, grow its team, and expand its customer base to meet the ever-evolving demands of the game industry.

To learn more about Mudstack, and experience a free trial, visit www.mudstack.com.

About Mudstack
Mudstack is building the next generation asset management and collaboration platform for artists, developers, and producers. It shortens development times by improving communication and collaboration across all members of the team, encourages risk-taking and creativity by ensuring no work is ever lost, and fosters the creation of community by opening up the development process to a global audience. The future of creative collaboration will be powered by continuous integration, automation, and AI. Mudstack aims to be at the forefront of this transformation.

For more information, visit mudstack.com.

SOURCE Mudstack, Inc.